Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Tec-Dara or Tec-Len in Elderly Newly Diagnosed Multiple Myeloma
2022-001594-31Phase 2Active
- Sponsor
- CHU de Lille
- Start
- Jul 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of teclistamab in multiple myeloma (MM) (2 arms), sponsored by CHU de Lille. Primary endpoint: Rate of VGPR or better after 4 cycles. Started Jul 2022; status: active.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-001594-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001594-31.